Brandicourt will leave Bayer HealthCare AG to begin his new role as CEO of Sanofi in April 2015.
Olivier Brandicourt will be the next chief executive officer of Sanofi, the company announced on Feb. 19, 2015. "Sanofi undertook a rigorous selection process to identify the right person to lead Sanofi forward at an important time for our company,” said Serge Weinberg, acting CEO and chairman of the board of directors at Sanofi, in a press release. "Olivier Brandicourt's strong experience combined with his international profile, deep knowledge of US and emerging healthcare markets, and his capability to unite teams will provide new dynamism to Sanofi's strategy of diversification and innovation."
Brandicourt, who has been chairman and CEO of Bayer HealthCare AG since 2013, will assume the new position at Sanofi on Apr. 2, 2015. He has held prior executive-level positions at Pfizer and Parke-Davis/Warner-Lambert, and he is a trained physician. He will replace former CEO Chris Viehbacher, who was ousted in October 2014.
Bayer agreed to release Brandicourt in April and announced in a separate statement that board member Werner Baumann will take over the function of chairman at Bayer HealthCare AG. Dr. Marijn Dekkers, chairman of the board of management of Bayer AG, thanked Brandicourt for his contributions to Bayer and wished him the best in his new role.
Source:
Sanofi
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.